Mitotane induces mitochondrial membrane depolarization and apoptosis in thyroid cancer cells.
Antineoplastic Agents, Hormonal
/ pharmacology
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
DNA Damage
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Membrane Potential, Mitochondrial
/ drug effects
Mitochondrial Proton-Translocating ATPases
/ metabolism
Mitotane
/ pharmacology
Thyroid Neoplasms
/ drug therapy
Journal
International journal of oncology
ISSN: 1791-2423
Titre abrégé: Int J Oncol
Pays: Greece
ID NLM: 9306042
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
22
08
2018
accepted:
12
03
2019
pubmed:
23
5
2019
medline:
21
12
2019
entrez:
23
5
2019
Statut:
ppublish
Résumé
Mitotane is used for the treatment of adrenocortical cancer and elicits its anticancer effects via inhibition of mitochondrial respiration. Targeting mitochondria‑dependent metabolism has emerged as a promising strategy for thyroid cancer (TC) treatment. We hypothesized that mitotane targets mitochondria and induces apoptosis in TC cells. Cell lines representative of the major histological variants of TC were chosen: Follicular (FTC‑133), poorly differentiated (BCPAP), anaplastic (SW1736 and C643) and medullary (TT) TC cells, and were treated with mitotane (0‑100 µM). Mitochondrial membrane potential, cell viability and apoptosis were examined by JC‑1 staining and by western blot analysis using an antibody against caspase‑3. The expression of mitochondrial molecules and DNA damage markers and the activation of endoplasmic reticulum (ER) stress were determined by western blotting. The expression of mitochondrial ATP synthase subunit β (ATP5B) was examined by immunostaining in 100 human TC tissue samples. Treatment with mitotane (50 µM for 24 h) decreased the viability of FTC‑133, BCPAP, SW1736, C643 and TT cells by 12, 59, 54, 31 and 66%, respectively. Morphological evidence of ER stress and overexpression of ER markers was observed in TC cells following exposure to mitotane. The treatment led to increased expression of histone γH2AX, indicating DNA damage, and to caspase‑3 cleavage. Consistent with the results of the cell viability assays, the overexpression of pro‑apoptotic genes following treatment with mitotane was more prominent in TC cells harboring mutations in the serine/threonine‑protein kinase B‑raf gene and proto‑oncogene tyrosine‑protein kinase receptor Ret. Treatment with mitotane was associated with loss of mitochondrial membrane potential and decreased expression of ATP5B, particularly in the medullary TC (MTC)‑derived TT cells. Immunohistochemical analysis of mitochondrial ATP5B in human TC specimens demonstrated its overexpression in cancer compared with normal thyroid tissue. The level of ATP5B expression was higher in MTC compared with the follicular, papillary or anaplastic types of TC. Mitotane elicited pleiotropic effects on TC cells, including induction of ER stress, inhibition of mitochondrial membrane potential and induction of apoptosis. The results of the present study suggest that mitotane could be considered as a novel agent for the treatment of aggressive types of TC.
Identifiants
pubmed: 31115496
doi: 10.3892/ijo.2019.4802
pmc: PMC6561621
doi:
Substances chimiques
ATP5F1B protein, human
0
Antineoplastic Agents, Hormonal
0
Mitotane
78E4J5IB5J
Mitochondrial Proton-Translocating ATPases
EC 3.6.3.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7-20Références
Toxicology. 2001 Aug 28;165(2-3):171-8
pubmed: 11522375
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Lancet. 2003 Feb 8;361(9356):501-11
pubmed: 12583960
Endocr Relat Cancer. 2005 Sep;12(3):667-80
pubmed: 16172199
Cancer Res. 2007 Sep 1;67(17):8113-20
pubmed: 17804723
Endocr Relat Cancer. 2008 Mar;15(1):37-49
pubmed: 18310274
Oncogene. 2008 Oct 27;27(50):6407-18
pubmed: 18955969
Cancer. 2009 Aug 15;115(16):3801-7
pubmed: 19598221
J Clin Oncol. 2009 Sep 20;27(27):4619-29
pubmed: 19667279
Endocrinology. 2010 Jun;151(6):2453-61
pubmed: 20392828
Clin Oncol (R Coll Radiol). 2010 Aug;22(6):486-97
pubmed: 20418080
Ann N Y Acad Sci. 2010 Jul;1201:21-5
pubmed: 20649534
Mod Pathol. 2011 Apr;24 Suppl 2:S19-33
pubmed: 21455198
J Clin Endocrinol Metab. 2011 Jun;96(6):1844-51
pubmed: 21470991
Endocr Relat Cancer. 2012 May 24;19(3):447-56
pubmed: 22389381
Eur J Endocrinol. 2012 Oct;167(4):473-81
pubmed: 22815335
Ann Oncol. 2012 Oct;23 Suppl 7:vii131-8
pubmed: 22997446
Thyroid. 2012 Nov;22(11):1104-39
pubmed: 23130564
J Clin Endocrinol Metab. 2013 Jan;98(1):161-71
pubmed: 23162091
Front Endocrinol (Lausanne). 2012 Nov 16;3:133
pubmed: 23162534
Mol Med Rep. 2013 Mar;7(3):893-900
pubmed: 23254310
Endocr Relat Cancer. 2013 May 21;20(3):371-81
pubmed: 23696597
Thyroid. 2014 Feb;24(2):232-40
pubmed: 23721245
Endocr Relat Cancer. 2013 Jun 27;20(4):537-50
pubmed: 23722227
Oxid Med Cell Longev. 2013;2013:351613
pubmed: 23819011
Endocr Relat Cancer. 2014 May 06;21(3):R183-94
pubmed: 24446492
J Clin Endocrinol Metab. 2014 May;99(5):E734-45
pubmed: 24483157
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
N Engl J Med. 2014 Nov 6;371(19):1765-7
pubmed: 25372084
Endocrinol Metab Clin North Am. 2015 Jun;44(2):411-34
pubmed: 26038209
Clin Endocrinol (Oxf). 2016 Apr;84(4):614-9
pubmed: 26221968
Endocrinology. 2015 Nov;156(11):3895-908
pubmed: 26305886
Endocr Relat Cancer. 2016 Jan;23(1):R43-69
pubmed: 26475053
Expert Rev Clin Pharmacol. 2016 Oct;9(10):1299-1313
pubmed: 27367142
Endocr Relat Cancer. 2017 Mar;24(3):147-156
pubmed: 28137980
J Physiol Pharmacol. 2017 Feb;68(1):13-26
pubmed: 28456766
Oncotarget. 2017 Jul 4;8(66):109924-109940
pubmed: 29299119
Clin Cancer Res. 2018 Aug 15;24(16):4030-4043
pubmed: 29691295
Int J Endocrinol Metab. 2019 Jan 13;17(1):e67759
pubmed: 30881466
Cancer Treat Rep. 1986 Mar;70(3):405-7
pubmed: 3955552
Cancer. 1985 Feb 15;55(4):794-804
pubmed: 3967174
Am J Med. 1966 Oct;41(4):572-80
pubmed: 5923598
Eur J Cancer Clin Oncol. 1984 Jan;20(1):47-53
pubmed: 6537915
Surgery. 1983 Dec;94(6):926-31
pubmed: 6648806
Cancer Res. 1979 Jan;39(1):139-45
pubmed: 761184
Br J Cancer. 1994 May;69(5):947-51
pubmed: 8180029
N Engl J Med. 1998 Jan 29;338(5):297-306
pubmed: 9445411